Background. Guidelines for breast cancer staging exist, but adherence remains unknown. This study evaluates patterns of imaging in early stage breast cancer usually reserved for advanced disease. Methods. Surveillance Epidemiology, and End Results data linked to Medicare claims from 1992-2005 were reviewed for stage I/II breast cancer patients. Claims were searched for preoperative performance of computed tomography (CT), positron emission tomography (PET), bone scans, and brain magnetic resonance imaging (MRI) (''advanced imaging'').
under greater scrutiny to provide justification for expensive studies. This is particularly likely because metastatic disease is rarely found in patients clinically judged to have early stage breast cancer. 4 This study was performed to evaluate patterns of imaging in early stage breast cancer that is usually reserved for advanced stage disease and to discern whether the claims suggest, via the diagnosis codes, that these studies were consistent with national guidelines.
METHODS
Data were derived from Medicare claims linked to the National Cancer Institute's (NCI) Surveillance Epidemiology and End Results (SEER) database, with approval of the NCI. 5 Patients included had breast cancer diagnosed at C65 years of age between 1992 and 2005. All patients had cancer-directed surgery and were not enrolled in a health maintenance organization (HMO), having Medicare parts A and B, to provide a low likelihood of missing data. Patients were excluded if they had American Joint Committee on Cancer (AJCC) stage 0, III, or IV disease, if their disease was of unknown stage, if their first physician encounter or therapy date was unknown, or if they did not have standard therapy on one operative date (i.e., a simultaneous breast and nodal staging procedure), making the preoperative interval indeterminate. Patients receiving preoperative radiotherapy or chemotherapy, or those having treatment in an unknown order were excluded.
Claims were searched for performance of ''advanced imaging'' in the preoperative interval, defined as CT, brain MRI, bone scans, and PET. The start of the preoperative interval was defined by the first physician encounter having a breast-related diagnosis code \ 1 year before surgery. The end of the preoperative interval was the date on which a breast excision or mastectomy was performed simultaneously with nodal staging. As procedure codes for excisional biopsies and lumpectomies are sometimes used interchangeably, this allowed inference of therapeutic intent from the concurrent nodal procedure. ''Early stage'' here refers to AJCC stage I or II.
Claims were searched for the current procedural terminology (CPT) codes and International Classification of Diseases, Revision 9 (ICD-9), procedure codes listed in Table 1 . Physician claims were searched first, supplemented by outpatient and inpatient hospital claims. If conflicts arose between CPT codes and ICD-9 procedure codes, whose descriptions are less specific, CPT data were preferentially used. Conflicts between physician and outpatient hospital claims utilized physician claims. ICD-9 diagnosis codes associated with each imaging study were also reviewed.
Stage-specific estimates of advanced imaging use by year of diagnosis were determined as the proportion of cases with at least one claim in the preoperative interval. Trends were evaluated with the Cochran-Armitage test. Multivariable logistic regression was used for inferences about the relationship of advanced imaging use with predictive factors including patient demographics, tumor characteristics, and standard imaging. Predictors were included as categorical variables, and odds ratios reported relative to the reference level. Per NCI privacy requirements, groups involving fewer than 11 patients may not be detailed for reasons of privacy, and they were listed as \ 11. Statistical significance was set at P = 0.05 (twosided). Analyses were performed by SAS software, version 9.2 (SAS Institute) and Stata software, release 12 (StataCorp).
RESULTS
Between 1992 and 2005, there were 67,874 SEERMedicare stage I and II breast cancer patients. Cohort characteristics are listed in Table 2 . The majority of patients were female (99.1 %), white (89.5 %), and lived in metropolitan areas (84.4 %). Ductal histology was most common (86.7 %), and most patients had either estrogen receptor-or progesterone receptor-positive tumors (73.5 %). The patient population was closely divided between stage I (57.7 %) and II (42.3 %) breast cancer.
The advanced imaging trends performed in the preoperative interval over the study period demonstrated that 6,415 patients (9.5 %) received C1 CT scan, with patients receiving a CT scan increasing from 5.7 % (n = 201) in 
The total number of patients having C1 PET scan was 706 (1.0 %), increasing from 0.8 % (n = 27) to 3.4 % (n = 229) during the study period (trend, P \ 0.0001). There were 500 patients (0.7 %) having C1 brain MRI, with the proportion increasing from \ 11 to 1.1 % (n = 73) (trend, P \ 0.008). There were 9,446 patients (13.9 %) undergoing a bone scan, with those receiving C1 bone scan declining from 20.1 % (n = 704) in 1992 to 10.7 % (n = 716) in 2005 (trend, P \ 0.0001), as illustrated in Fig. 1 . Diagnosis codes were reviewed to see whether they provided a rationale suggesting that there was guidance offered to the radiologist performing the studies (Table 3) . Among 783 claims for PET scans between 1992 and 2005, 62.1 % (n = 486) had a diagnosis code for ''breast cancer'' (174.x) as the only code used on the claim. Only 13.0 % (n = 92) of patients had C1 sign or symptom (such as abdominal pain, abnormal physical finding, or abnormal laboratory value) listed on their claim as a reason for the study. There were 10,100 bone scan claims during the period of study. Of those, 37.7 % (n = 3,808) had ''breast cancer'' as the only diagnosis code given. Only 19.6 % (n = 1853) of patients had a sign or symptom consistent with NCCN guidelines (such as bone pain, joint pain, or abnormal laboratory values) listed on the claim. During the study period, there were 12,862 CT scans performed, with 24.2 % (n = 3,106) having ''breast cancer'' as the only diagnosis code provided. Only 13.0 % (n = 834) of patients had a diagnosis code supportive of guidelines appended to their CT scan claims. There were 552 brain MRI performed from 1992 to 2005, and only 5.1 % (n = 28) had ''breast cancer'' as the sole diagnosis code given, with 6.2 % (n = 31) of patients having a neurological sign or symptom indicated on the claim as the reason for the study.
Several factors significantly predicted advanced imaging use, as listed in Table 2 , and three factors predicted the use of all four advanced imaging modalities: urban or rural setting, whether patients underwent a breast MRI, and whether they had a breast ultrasound. If patients were from a big metropolitan area (population C1,000,000), versus a rural setting, they were more likely to have advanced imaging (Table 4 ). The strongest predictor of preoperative advanced imaging was breast MRI, as illustrated by the odds ratio estimates. If patients underwent breast MRI, they were 1.63 times as likely to receive a bone scan, 1.74 times as likely to receive a brain MRI, 2.42 times as likely to have a CT scan, and 5.71 times as likely to have a PET scan, when compared with those who did not undergo a breast MRI (Table 4) .
Histology and mammography were correlated with use of CT scans, bone scans, and brain MRI. Patients were more likely to have advanced imaging if their cancer was of lobular histology and they had a mammogram in the preoperative interval. Among those not having a mammogram in the preoperative interval, an additional 49.4 % (n = 33,559) patients had a mammogram before the preoperative interval, bringing the total to 96.1 %. Stage was significant for use of CT scans, bone scans, and PET scans in the preoperative interval, with stage II patients receiving these tests more frequently than stage I patients ( Table 2) .
Tumor grade and receptor status also predicted two imaging modalities. Patients having poorly differentiated tumors were more likely to receive bone or PET scans than those having well-differentiated tumors. Patients with estrogen receptor-and progesterone receptor-negative tumors were also more likely to undergo a bone or PET scan than patients having receptor-positive tumors. Race was a significant predictor of bone scan and CT scan use, with black or Asian patients having more advanced imaging than whites (Table 2) .
DISCUSSION
We have found that although the overall rate of preoperative advanced imaging for early stage Medicare breast cancer patients is low, aside from bone scans, use is increasing. The percentage of patients receiving CT scans more than doubled from 1992 to 2005, while there was a 4-fold increase in patients receiving PET scans and 5-fold increase in brain MRI. PET scan use was low before its U.S. Food and Drug Administration approval in 1997 but began markedly increasing after 2001 when approved by the Medicare Coverage Advisory Committee (Fig. 1) . 6 Conversely, there were half as many patients receiving bone scans in 2005 as in 1992.
Factors predicting advanced imaging use included a higher likelihood in patients from large population centers, which may also reflect the setting of the clinician ordering the study. This is not surprising: larger hospitals and cancer centers are more likely to be located in more populated areas, where concentrated resources and access to more advanced imaging technologies may exist. Although one could argue that larger, possibly academic, centers should be the most knowledgeable about current guidelines, easy access to technology and patient demand in these settings may encourage use of these additional tests. Although this should not theoretically enter into decision making, concern about litigation may reinforce such patient demands, especially among surgeons who are frequent targets of malpractice lawsuits and radiologists who overestimate their risk of being sued. 7, 8 Interestingly, patients who had a breast MRI were more likely to have advanced imaging performed. Although this association existed when adjusting for urban/rural setting, this may support the notion that practitioners having greater access to imaging resources (regardless of urban/ rural setting), use it more liberally. Preoperative breast MRI has been associated with tumor size overestimation and false-positive results, leading to unnecessary biopsies. Not only does MRI result in downstream tests such as second-look ultrasounds and short-term follow-up MRI, but with an 8-40 % incidence of occult lesions seen solely on breast MRI, such findings might prompt concern that distant occult lesions exist as well. [9] [10] [11] If a physician has a sufficiently low threshold to order a breast MRI when it may have marginal benefit, the same low threshold may apply to use of advanced imaging. Although the specific reasons for the association cannot be determined, imaging overuse is of great importance in light of the increasing proportion of total costs that imaging studies account for in breast cancer patients. 12 Patients with lobular histology and those with receptornegative tumors were more likely to undergo advanced imaging, although not all four modalities. Lobular carcinoma can be more difficult to detect and is often found at a later stage than ductal carcinoma. 13 Although the survival rates for these are identical, the later presentation may also account for the associated use of advanced imaging. Although estrogen receptor-positive tumors are often thought to have a better prognosis, this is controversial, and tumor phenotype (triple negative, luminal, etc.), which is not available from these data, may also correlate to imaging use.
14 It must be noted, however, that although these factors were associated with certain modalities, there was little clinical difference, as illustrated by the odds ratios in Table 4 . We also noted that outside of bone scans, age was not a determinant of advanced imaging. This is surprising because the ages of patients who received such studies were distributed well into their 80 s, and the benefit conferred to this older population remains unclear.
Stage II patients were more likely to have a bone, CT, or PET scan when compared with stage I patients. Although the likelihood of finding metastatic disease for stage II patients is slightly higher than stage I, it remains low. 4, 15, 16 Gerber et al. evaluated tumor size and nodal status for their associations with occult metastases. 17 In this study of 1,076 patients, distant metastases were only found with 1.6 % and 3.0 % of T1 and T2 tumors, respectively. They also found that only 1.9 % and 1.8 % of patients with N0 and N1 disease, respectively, had distant metastases. In our study, overall stage was used, and this information should be applicable to our results. Because clinical stage cannot be assessed by SEER (or Medicare) data and only final pathologic stage is recorded, it remains unclear how many patients may have been judged preoperatively as having a more advanced clinical stage until these studies were performed. a For example, ''secondary malignant neoplasm of bone or bone marrow'' as an indication for a bone scan describes what the study is looking for (bone metastases), but not why the study is being ordered-that is, what symptom or sign elicits suspicion for that concern and justification for performance of the study. n represents the number of imaging claims, not patient numbers 15 Bone scans detected skeletal metastases in only 0.5 % of women with stage I breast cancer, 2.4 % of stage II, and 8.3 % of stage III. Similarly, they found that routine liver ultrasound detected liver metastases in 0 % of stage I, 0.4 % of stage II, and 2.0 % of stage III patients. Chest radiography also detected very few lung metastases, at 0.1 %, 0.2 %, and 1.7 % in patients with stage I, II, and III disease, respectively. They also noted false-positive rates for these imaging modalities, ranging from 0 to 66 %, depending on the study, concluding that routine use of staging studies in stage I and II breast cancer patients is not indicated.
Brennan and Houssami performed a meta-analysis evaluating the prevalence of distant metastases in asymptomatic patients with breast cancer. 4 The prevalence of distant metastases in stage I patients ranged from 0 to 5.1 % with a median of 0.2 %. The prevalence of distant metastases in stage II patients ranged from 0 to 34.3 % with a median of 1.2 %. Of note, one study reported 34.3 % of patients having distant metastases, but this study combined stage IIB and III patients, limiting its relevance here. 18 Although multiple studies reported that advanced imaging has a very low yield in identifying distant metastases, we have found that in the Medicare patient, use of these tests is on the rise, with little rationale to support the increase.
As is standard for SEER-Medicare analyses, patients were excluded who were enrolled in a HMO because such patients may not have complete claims information. 19 Although the data here are representative of the Medicare population, these trends may not be applicable to either the privately insured or the uninsured population. Breast cancer is a diagnosis of older age (mean age at diagnosis is 61 years), so the findings herein may represent a significant proportion of breast cancer patients in the United States. 20 It must also be recognized that although the diagnosis codes only supported current indications in a minority of claims, this may be the result of poor coding and may not reflect rationales provided on the actual imaging orders, which are not available for review. The majority of claims listed a breast-related issue as the primary diagnosis (e.g., 174.x ''malignant breast neoplasm'' or V10.3 ''personal history of malignant breast neoplasm'') or had a diagnosis that was not cancer related (e.g., V72.5 ''radiological examination, not elsewhere classified'' or 401.9 ''unspecified essential hypertension''). Although all imaging reviewed for this study occurred in the preoperative interval, it is difficult to determine what was performed for staging, versus other medical reasons. We think that this is still problematic, however, because these codes provide the sole justification for their use and reimbursement.
Unfortunately, the specialty of the physician ordering the studies, versus performing them, is not available in the SEER-Medicare database; it would be interesting to see whether specialty, work experience, or patient volume correlated to imaging use. Although we may not be able to deduce the exact reason for the performance of these studies, it is clear that the amount of imaging being done in stage I and II breast cancer patients is increasing. This study did not evaluate whether claims were denied, but the intent was to assess what is being ordered, rather than what has been approved or denied by Medicare.
Finally, there may have been a larger number of patients deemed to have stage I or II disease clinically in the preoperative period who underwent imaging, among whom a proportion were found to have metastases. Because only the final pathologic stage is recorded by SEER, these patients would have been solely listed as stage IV and excluded from this analysis. In that same vein, changing sensitivities of the technology of these imaging modalities may also affect the trends seen here.
The significance of our findings is in part related to health care costs that have been increasing, especially among cancer patients. In a study of Medicare cancer patients, not only was the amount of imaging per patient increasing, but the cost of imaging accounted for an increasing proportion of all cancer costs over time. 12 For breast cancer patients specifically, the average total cost per patient increased 4.1 % annually, from $23,549 to $33,609 over the course of the study. The imaging costs per patient increased from $840 to $1,681, corresponding to an annual increase of 9.9 %-more than double that of the total cost. Our data provide one potentially contributing factor for these findings. With progressively fewer health care resources per capita, greater justification will be required for tests that have an outcome benefit. Meanwhile, reinforcement and better dissemination of indications for advanced imaging in breast cancer patients should be pursued. 
